Abstract
Ischemic heart disease remains a pressing global health problem. Among modern therapeutic strategies, percutaneous coronary intervention (PCI) plays a key role in relieving myocardial ischemia and improving long-term prognosis in many patients. However, the post-PCI period is often complicated by various adverse events, including restenosis, stent thrombosis, and, importantly, bleeding events, which represent one of the major clinical challenges. Therefore, in the management of patients after PCI, careful assessment of risk factors, as well as the accurate selection of both the duration and composition of antiplatelet therapy, is of paramount importance.